News

National Brain Tumor Society Statement on New Biden-Harris Cancer Moonshot Goals National Brain Tumor Society (NBTS), a leader in brain tumor patient advocacy, research, information, and support, was honored to represent the millions of Americans impacted by brain tumors every year at a White House event to reignite the Cancer Moonshot.  The following is a statement from NBTS chief executive officer, David Arons, on today’s announcement. […] February 2, 2022

Widely-available Drug May Benefit Glioblastoma Treatment Based on data from NBTS’s Defeat GBM Research Collaborative and with support from the Sharpe family, Dr. Paul Mischel (Stanford University) and his laboratory team found that the antidepressant drug, fluoxetine (common brand name: Prozac), potently targets tumor metabolism and inhibits epidermal growth factor (EGFR) signaling, triggering the killing of glioblastoma (GBM) cells. Dr. Mischel’s […] December 17, 2021

Years of Scientific Progress Lead to Hope for Glioblastoma Patient With funding from the National Brain Tumor Society, Clark C. Chen, MD, PhD of the University of Minnesota is ready to start a clinical trial for a drug that is already showing early promise for a glioblastoma patient. The following blog, which has been lightly edited, was originally published on the University of Minnesota’s Neurosurgery […] November 4, 2021

Advocacy in Action: Updates on the Childhood Cancer STAR Act and Childhood Cancer Data Initiative The Childhood Cancer STAR Act and Childhood Cancer Data Initiative (CCDI) are major federal government-led initiatives that exist in part because of years of advocacy work by members of the brain tumor and childhood cancer communities. As we reflect back on Childhood Cancer Awareness Month (CCAM) this past September, we want to share updates on […] October 8, 2021

Innovating Brain Tumor Clinical Trials: Lessons Learned During the COVID-19 Experience The global COVID-19 pandemic disrupted nearly every facet of life in 2020, and brain cancer research, particularly clinical trials, was not spared from its impacts. As is often the case, though, with disruption comes the opportunity to innovate. Convening key stakeholders across the brain tumor community, the National Brain Tumor Society (NBTS) has taken stock […] May 7, 2021